Prusogliptin

Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.
Wikipedia contributors, "Prusogliptin", Wikipedia, revision 1330457733, retrieved 20 November 2026, source, CC BY-SA 4.0.